Dateline City:
KENILWORTH, N.J.
Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission (EC) has approved KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, at a dose of 2 mg/kg
every three weeks, for patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) in patients whose tumors express
PD-L1 and who have received at least one prior chemotherapy regimen.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more